Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $70.02 +1.49%
Revenue Growth %: +23.1%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +23.1%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $661.33 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
